Amylyx Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Amylyx Pharmaceuticals, Inc. | AMLX - NASDAQ |
$18.00-$20.00 |
$19.00 |
$21.00 | 10 million | 1/7/2022 |
Goldman Sachs, SVB Leerink, Evercore ISI |
Co-Manager(s): HC Wainwright |
Health Care |
Filing(s): Filed 2021-12-17 Terms Added 2022-01-03
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Amylyx Pharmaceuticals, Inc. , and our comprehensive analysis, click "Buy Market Research".
Amylyx Pharmaceuticals, Inc. Quote & Chart - Click for current quote -
AMLX
About Amylyx Pharmaceuticals, Inc. (adapted from Amylyx Pharmaceuticals, Inc. prospectus):
Their mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AMLX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved